Linkage receives $2m boost for molecular Dx
This article was originally published in Clinica
Executive Summary
Linkage Biosciences has secured $2m to help develop its line of molecular diagnostic tests after closing a series A financing round. The funding was led by Greenhouse Capital and James Fisher, a managing member of Fisher Capital. San Francisco, California-based Linkage said that the new capital would be used to further the development and marketing of its test for human leukocyte antigen (HLA) typing, used in organ transplantation to detect whether or not a body will reject foreign tissues. The company also said it was looking to develop a portfolio of diagnostics in other areas of transplantation.